Prescription of oral antidiabetic drugs in K/DIGO chronic kidney disease stage 3 and 4: A single centre report

Minerva Urologica e Nefrologica

Volumn 66, Issue 1, 2014, Pages 69-75

  Fabbian, F ^a   De Giorgi, A ^a   Monesi, M ^a   Tiseo, R ^a   Storari, A ^a   Menegatti, A Mallozzi ^a   Pala, M ^a   Tomasi, F ^a   Portaluppi, F ^a   Manfredini, R ^a  

^a UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

Chronic kidney disease; Diabetes mellitus; Glomerular filtration rate

Indexed keywords

CREATININE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; METFORMIN; REPAGLINIDE; SULFONYLUREA;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIABETOLOGIST; DIASTOLIC BLOOD PRESSURE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PHYSICIAN; PRESCRIPTION; SYSTOLIC BLOOD PRESSURE;

AGED; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX;

EID: 84901825214     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Wang W. Zhao D, Xing Y, Li J, Hu D, Xu Y, Merriam PA, Ma Y. Clinical features of Chinese coronary artery disease patients with chronic kidney disease. Ren Fail 2012;34:985-90.
2. Deshmukh AB, Patel MC, Mishra B. SGLT2 inhibition: a novel prospective strategy in treatment of diabetes mellitus. Ren Fail 2013;35:566-72.
3. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA 2004;291:844-50. (Pubitemid 38543772)
4. Registro Italiano di Dialisi e Trapianto [Internet]. Available at http://www.sin-ridt.org/italia/report 2009 [cited 2012, Mar 7].
5. Meyers JL, Candrilli SD, Kovacs B. Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and hyperglycaemic medication dose adjustment. Postgrad Med 2011;123:133-43.
6. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12.
7. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int (Suppl.)2013;3:1-150.
8. National Kidney Foundation. Diabetes and chronic kidney disease: stages 1-4 [Internet], Available at http://www.kideny.org/atoz/pdf/diabets.pdf. Accessed 19/02/2013 [cited 2013, Nov 18].
9. Plantinga LC, Crews DC, Coresh J, Miller ER 3rd, Saran R, Yee J, Hedgeman E et al. CDC CKD Surveillance Team. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol 2010;5:673-82.
10. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 2009;52:17-30.
11. Reilly JB, Berns JS. Selection and dosing of medications for management of diabetes in patients with advanced kidney disease. Semin Dial 2010;23: 163-8.
12. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospuitalizations for adverse drug events in older Americans. N Engl J med 2011;365:2002-12.
13. Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metyabolism and clinical practice. Curr Drug Metab 2011;12:57-69
14. Rodbard HW, Jellinger PS, Davidson JA, Einhom D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-559.
15. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al. American Diabetes Association;European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes:a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
16. del Pozo-Fernández C, Pardo-Ruiz C, Sánchez-Botella C, Blanes-Castañer V, López-Menchero R, Gisbert-Sellés C et al. Discrepancies among consensus documents, guidelines, clinical practice and the legal framework for the treatment of type 2 diabetes mellitus patients. Nefrologia 2012;32:367-73.
17. Vasisht KP, Chen S-C, Peng Y, Bakris GL. Limitations of metformin use in patients with kidney disease: are they warranted? Diabet Obes Metabol 2010;12:1079-83.
18. Holstein A, Plaschke A, Hammer C, Egberts EH. Characteristics and time course of severe glimepiride-versus glibenclamide-induced hypoglycaemi. Eur J Clin Pharmacol 2003;59:91-7. (Pubitemid 36793719)
19. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011;34:1431-7.
20. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010;CD002967.
21. Pirkle JL, Freedman BI. Hypertension and chronic kidney disease: controversies in the pathogenesis and treatment. Minerva Urol Nephrol 2013;65:37-50.
22. Magri CJ, Fava S. Albuminuria and glomerular filtration rate in type 2 diabetes mellitus. Minerva Urol Nephrol 2011;63:273-280
23. Eurich DT, McAlister FA, Blackburn DF, Majumdar SR, Tsuyuki RT, Varney J et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007:335:497.
24. Tzoulaki I, Molokhia M, Curcin U, Little MP, Millett CJ, Ng A et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731.